MetaCap

Cartesian Therapeutics (RNAC) vs Yarrow Bioscience (YARW)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cartesian Therapeutics (RNAC) has outperformed Yarrow Bioscience (YARW) over the past year, losing 15.2% versus a loss of 26.7%. Over five years, RNAC leads with a -92.9% price change compared with -98.6% for YARW. Yarrow Bioscience is the larger company by market cap ($196.5 million vs $187.3 million), about 1.0 times the size.

Yarrow Bioscience converts more of its revenue into profit, with a net margin of -4646.1% versus -4658.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RNAC-15.19%YARW-26.70%
+172%+68%-36%
Nov 21, 20251 yearNov 20, 2026
RNAC-93.62%YARW-98.66%
+47%-29%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RNAC versus YARW key metrics
MetricRNACYARW
Share price$6.14$12.90
Market cap$187.29M$196.53M
1-day change+4.24%-9.35%
YTD return-14.84%-55.52%
1-year return-15.19%-26.70%
5-year return-92.94%-98.61%
EPS (TTM)$-4.78—
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.80M$570.00K
Revenue growth (YoY)-92.81%+13.77%
Net income (latest FY)$-130.30M$-26.48M
Operating margin-5127.10%-5219.12%
Net margin-4658.63%-4646.14%
52-week high$11.00$46.95
52-week low$5.60$12.39
Distance from 52-week high-44.18%-72.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+448.37%+310.85%
Average volume139.65K153.34K
Shares outstanding30.50M15.23M
Employees757
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RNAC has outperformed YARW by 11.5 percentage points over the past year.
  • Yarrow Bioscience is more profitable, keeping -4646.1 cents of every revenue dollar as net income versus -4658.6 cents for Cartesian Therapeutics.
  • Yarrow Bioscience grew revenue faster in its latest fiscal year (+13.77% vs -92.81%).

About Cartesian Therapeutics

RNAC stock →

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About Yarrow Bioscience

YARW stock →

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

RNAC vs YARW FAQ

Which is bigger, Cartesian Therapeutics or Yarrow Bioscience?

Yarrow Bioscience (YARW) is larger, with a market capitalization of $196.53M compared with $187.29M for Cartesian Therapeutics (RNAC).

Which stock has performed better over the past year, RNAC or YARW?

RNAC returned -15.19% over the past 12 months, compared with -26.70% for YARW (price return, excluding dividends). Past performance does not predict future results.

Are Cartesian Therapeutics and Yarrow Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons